Sun Pharma gains 1% on launching Xelpros in the US

SPARC had out-licensed the Xelpros brand to Sun Pharma in June 2015.

Jan 14, 2019 09:01 IST India Infoline News Service

Shares of Sun Pharma Advanced Research Company gained 1% in intraday trade on Monday as the pharma giant commercialized Xelpros (Latanoprost ophthalmic emulsion) 0.005%.

SPARC had out-licensed the Xelpros brand to Sun Pharma in June 2015, and this commercialization of Xelpros has triggered a milestone payment of $10mn and sales-linked royalties by Sun Pharma to SPARC. Read more. 

Sun Pharma Advanced Research Company Ltd is currently trading at Rs185 up by Rs1.2 or 0.65% from its previous closing of Rs183.80 on the BSE.
The scrip opened at Rs191.50 and has touched a high and low of Rs192 and Rs183.80 respectively. So far 9,46,899 (NSE+BSE) shares were traded on the counter. 


Related Story